Buchumschlag

Long-term remission in a patient with heavily pretreated, advanced ovarian cancer achieved by bevacizumab and metronomic cyclophosphamide treatment

Vascular endothelial growth factor seems to be a promoter of tumor progression for epithelial ovarian cancer. New drugs such as bevacizumab, either alone or in combination with metronomic chemotherapy, suppress tumor growth and have proved to be effective in various tumor types. We present a 60-year...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Aigner, Julia (VerfasserIn) , Bischofs, Esther (VerfasserIn) , Hallscheidt, Peter (VerfasserIn) , Sohn, Christof (VerfasserIn) , Schneeweiss, Andreas (VerfasserIn) , Eichbaum, Michael H. R. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2011
In: Anti-cancer drugs
Year: 2011, Jahrgang: 22, Heft: 10, Pages: 1030-1033
ISSN:1473-5741
DOI:10.1097/CAD.0b013e32834a62b4
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1097/CAD.0b013e32834a62b4
Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/anti-cancerdrugs/Fulltext/2011/11000/Long_term_remission_in_a_patient_with_heavily.12.aspx
Volltext
Verfasserangaben:Julia Aigner, Esther Bischofs, Peter Hallscheidt, Christof Sohn, Andreas Schneeweiss and Michael Eichbaum
Beschreibung
Zusammenfassung:Vascular endothelial growth factor seems to be a promoter of tumor progression for epithelial ovarian cancer. New drugs such as bevacizumab, either alone or in combination with metronomic chemotherapy, suppress tumor growth and have proved to be effective in various tumor types. We present a 60-year-old patient with heavily pretreated, recurrent epithelial ovarian cancer, who received bevacizumab (10 mg/m2) every 2 weeks in combination with metronomic administered low-dose cyclophosphamide (50 mg/day orally) after failing four explorative laparotomies and multiple chemotherapy regimes. At the time of writing, February 2011, she was being treated with this combination therapy for 24 months and the progression-free survival still continues. Treatment of advanced, refractory epithelial ovarian cancer with bevacizumab in combination with low-dose cyclophosphamide could be a very effective salvage treatment option in heavily pretreated patients.
Beschreibung:Gesehen am 28.02.2022
Beschreibung:Online Resource
ISSN:1473-5741
DOI:10.1097/CAD.0b013e32834a62b4

Ähnliche Einträge